Published in Infect Immun on May 01, 2001
Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun (2002) 2.44
Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev (2005) 2.36
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev (2011) 1.87
Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis (2013) 1.84
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun (2001) 1.62
PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun (2005) 1.54
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun (2008) 1.42
Acquisition of regulators of complement activation by Streptococcus pyogenes serotype M1. Infect Immun (2002) 1.24
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Pneumococcal surface protein C contributes to sepsis caused by Streptococcus pneumoniae in mice. Infect Immun (2004) 1.15
Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3. Infect Immun (2005) 1.14
The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun (2002) 1.14
Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem (2010) 1.13
The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype. Infect Immun (2009) 1.11
Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I. Infect Immun (2004) 1.10
Involvement of potD in Streptococcus pneumoniae polyamine transport and pathogenesis. Infect Immun (2006) 1.09
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
Analysis of a unique interaction between the complement regulatory protein factor H and the periodontal pathogen Treponema denticola. Infect Immun (2009) 1.09
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis. J Biol Chem (2008) 1.08
Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells. Immunology (2007) 1.05
Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05
The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05
Impact of the SpeB protease on binding of the complement regulatory proteins factor H and factor H-like protein 1 by Streptococcus pyogenes. Infect Immun (2005) 1.04
The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect Immun (2006) 1.03
Subterfuge and sabotage: evasion of host innate defenses by invasive gram-positive bacterial pathogens. Annu Rev Microbiol (2014) 1.00
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
The Streptococcus pneumoniae pilus-1 displays a biphasic expression pattern. PLoS One (2011) 0.99
Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins. Eur J Clin Microbiol Infect Dis (2010) 0.98
Identification of an antiparallel coiled-coil/loop domain required for ligand binding by the Borrelia hermsii FhbA protein: additional evidence for the role of FhbA in the host-pathogen interaction. Infect Immun (2008) 0.98
Biofilm formation avoids complement immunity and phagocytosis of Streptococcus pneumoniae. Infect Immun (2013) 0.98
Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One (2011) 0.97
New adhesin functions of surface-exposed pneumococcal proteins. BMC Microbiol (2010) 0.95
Factor H binding to PspC of Streptococcus pneumoniae increases adherence to human cell lines in vitro and enhances invasion of mouse lungs in vivo. Infect Immun (2007) 0.94
Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infect Immun (2010) 0.93
Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation. FASEB J (2009) 0.93
Pneumococci in biofilms are non-invasive: implications on nasopharyngeal colonization. Front Cell Infect Microbiol (2014) 0.90
Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem (2014) 0.88
Differential role of CbpA and PspA in modulation of in vitro CXC chemokine responses of respiratory epithelial cells to infection with Streptococcus pneumoniae. Infect Immun (2006) 0.87
Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol (2011) 0.87
Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response. Infect Immun (2014) 0.85
Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage. Mucosal Immunol (2015) 0.85
Crystallization of the factor H-binding protein, FhbB, from the periopathogen Treponema denticola. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.84
Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media. Int J Pediatr Otorhinolaryngol (2014) 0.83
Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus. Clin Vaccine Immunol (2012) 0.82
Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine. Clin Vaccine Immunol (2013) 0.81
Complement Evasion Mediated by Enhancement of Captured Factor H: Implications for Protection of Self-Surfaces from Complement. J Immunol (2015) 0.80
Localization of PcsB of Streptococcus pneumoniae and its differential expression in response to stress. J Bacteriol (2007) 0.80
Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection. Clin Vaccine Immunol (2015) 0.80
Molecular Characterization of Pneumococcal Surface Protein K, a Potential Pneumococcal Vaccine Antigen. Virulence (2017) 0.80
Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New Antimicrobials. Antibiotics (Basel) (2016) 0.79
Interaction between M-like protein and macrophage thioredoxin facilitates antiphagocytosis for Streptococcus equi ssp. zooepidemicus. PLoS One (2012) 0.79
Binding of human factor H to outer membrane protein P5 of non-typeable Haemophilus influenzae contributes to complement resistance. Mol Microbiol (2014) 0.78
Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC. Clin Vaccine Immunol (2012) 0.78
Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC. Clin Vaccine Immunol (2014) 0.76
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Mechanisms of Host-Pathogen Protein Complex Formation and Bacterial Immune Evasion of Streptococcus suis Protein Fhb. J Biol Chem (2016) 0.75
A novel monoclonal antibody against FbaA can inhibit the binding of the complement regulatory protein factor H to group A streptococcus. Clin Vaccine Immunol (2011) 0.75
Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae. Front Cell Infect Microbiol (2016) 0.75
Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. Annu Rev Genet (2015) 0.75
Elevated complement factor H levels in asthmatic sputa. J Clin Immunol (2012) 0.75
Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self surface-selective regulation of complement activation. J Biol Chem (2017) 0.75
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol (1997) 4.78
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol (1997) 3.01
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Pneumococcal disease: prospects for a new generation of vaccines. Science (1994) 2.48
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol Microbiol (2000) 1.56
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
C3 as substrate for adhesion of Streptococcus pneumoniae. J Infect Dis (2000) 1.48
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog (1992) 1.39
Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene (1997) 1.14
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med (1998) 3.03
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med (1998) 2.24
Heterogeneity among strains and a high rate of variation within strains of a major surface antigen of Mycoplasma pulmonis. Infect Immun (1988) 2.21
PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine (1996) 2.08
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med (2001) 1.91
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A (1996) 1.91
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol (1984) 1.72
Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis (1988) 1.70
PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist (1997) 1.67
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol (1999) 1.51
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
Species specificity of recognition by the alternative pathway of complement. J Immunol (1985) 1.49
Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates. J Biol Chem (1990) 1.49
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine (2000) 1.48
The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis. Mol Immunol (2000) 1.43
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clin Immunol Immunopathol (1982) 1.42
Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J Immunol (1986) 1.41
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett (1996) 1.38
Survival of recombination-deficient mutants of Escherichia coli during incubation with nalidixic acid. J Bacteriol (1978) 1.37
Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann N Y Acad Sci (1996) 1.34
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Biochemistry (1983) 1.30
Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun (1994) 1.26
The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J (1986) 1.26
Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem (1984) 1.26
Evidence of homologous relationship between thermolysin and neutral protease A of Bacillus subtilis. Proc Natl Acad Sci U S A (1975) 1.25
Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies. Microb Pathog (1988) 1.25
C3 modified at the thiolester site: acquisition of reactivity with cellular C3b receptors. Biosci Rep (1981) 1.25
Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun (1997) 1.24
Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci (1983) 1.17
Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin Immunol Immunopathol (1980) 1.16
A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement. J Immunol Methods (1987) 1.15
Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene (1997) 1.14
Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor. Arthritis Rheum (1980) 1.14
C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem (1998) 1.06
PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun (2012) 1.06
C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex. J Biol Chem (1983) 1.05
Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol (1993) 1.04
Selective inhibition of functional sites of cell-bound C3b by hybridoma-derived antibodies. J Immunol (1982) 1.04
Activation of complement via the alternative pathway. Fed Proc (1983) 1.03
C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. Int Immunopharmacol (2001) 1.03
Characterization of the initial C3 convertase of the alternative pathway of human complement. J Immunol (1984) 1.03
Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun (2001) 1.01
Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J Immunol (1986) 1.01
Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol (2000) 1.00
Detection of a neoantigen on human C3bi and C3d by monoclonal antibody. J Immunol (1985) 0.99
A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b. Eur J Immunol (1990) 0.97
Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system. Gene (1994) 0.94
Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein. Infect Immun (1997) 0.93
Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol (2000) 0.93
C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol (1990) 0.92
Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect Immun (1998) 0.92
Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation. J Biol Chem (1994) 0.92
Structure/function of C5 convertases of complement. Int Immunopharmacol (2001) 0.91
Cross-reactive protection eliciting epitopes of pneumococcal surface protein A. Ann N Y Acad Sci (1994) 0.90
Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem Pharmacol (1999) 0.89
Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem Pharmacol (1996) 0.87
Tyrosine is a potential site for covalent attachment of activated complement component C3. Mol Immunol (1995) 0.86
Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitis. J Clin Microbiol (1988) 0.85
Immunomodulation by Blastomyces dermatitidis: functional activity of murine peritoneal macrophages. Infect Immun (1983) 0.85
DNA polymorphisms and variant penicillin-binding proteins as evidence that relatively penicillin-resistant pneumococci in western Canada are clonally related. J Infect Dis (1996) 0.84
Complement alternative pathway activation and control on membranes of human lymphoid B cell lines. Eur J Immunol (1990) 0.84
Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transpl Immunol (2003) 0.84
Thermal stability of homologous neutral metalloendopeptidases in thermophilic and mesophilic bacteria: structural considerations. Experientia Suppl (1976) 0.81
Alternative pathway of complement. Methods Enzymol (1988) 0.81
Affinity chromatography of thermolysin and of neutral proteases from B. subtilis. Biochem Biophys Res Commun (1973) 0.81
Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B Streptococcus pneumoniae. Microb Pathog (1996) 0.80
Specific deposition of complement protein C3b on abnormal PNH erythrocytes permits their separation by partitioning. Possible general approach for isolation of specific cell populations. Biochim Biophys Acta (1987) 0.79